Genomic Testing Gap: Half of Metastatic Cancer Patients Miss Key Sequencing, Disparities Widen

A critical diagnostic step is being missed for a vast number of patients with advanced cancer, potentially locking them out of life-extending, targeted treatments. A new study reveals that for most metastatic cancers examined, only about half of patients ever receive genomic sequencing of their tumors—a foundational test to identify mutations that can be targeted by newer, precision drugs. This systemic failure means a significant portion of patients are navigating treatment without access to the full arsenal of modern oncology.

The research, published in JAMA Network Open, analyzed real-world data from patients diagnosed with one of five metastatic cancers. The findings expose stark disparities: patients with lower incomes, those covered by Medicare or Medicaid, and individuals who are Black or Hispanic were significantly less likely to have their tumors sequenced. This gap persists despite genomic profiling becoming a standard-of-care recommendation for many advanced cancers, suggesting that access to precision medicine is not equitable.

The implications are profound for both patient outcomes and healthcare systems. While overall cancer survival rates have improved dramatically—with the five-year survival rate for metastatic cancer doubling since the 1960s—this progress is not uniformly distributed. The study signals a major failure in the implementation of precision oncology, where systemic barriers and socioeconomic factors, rather than clinical guidelines, are dictating who benefits from the latest medical advances. This creates a two-tiered system where cutting-edge care is accessible only to some, undermining the potential of genomic medicine to transform cancer treatment for all.